Healthcare - Medical - Healthcare Information Services - NASDAQ - US
$ 0.0001
0 %
$ 888
Market Cap
0.0
P/E
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices.[ Read More ]
The intrinsic value of one UTRS stock under the base case scenario is HIDDEN Compared to the current market price of 0.0001 USD, Minerva Surgical, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart UTRS
FINANCIALS
50.3 M
REVENUE
-30.9 M
OPERATING INCOME
-34.1 M
NET INCOME
-35.6 M
OPERATING CASH FLOW
-73 K
INVESTING CASH FLOW
-4.96 M
FINANCING CASH FLOW
12 M
REVENUE
-6.1 M
OPERATING INCOME
-7.18 M
NET INCOME
-5.1 M
OPERATING CASH FLOW
-17 K
INVESTING CASH FLOW
0
FINANCING CASH FLOW
Balance Sheet Decomposition
Minerva Surgical, Inc.
| Current Assets | 36.1 M |
| Cash & Short-Term Investments | 6.94 M |
| Receivables | 7.24 M |
| Other Current Assets | 21.9 M |
| Non-Current Assets | 32.8 M |
| Long-Term Investments | 0 |
| PP&E | 5.31 M |
| Other Non-Current Assets | 27.5 M |
| Current Liabilities | 14.3 M |
| Accounts Payable | 2.8 M |
| Short-Term Debt | 2.25 M |
| Other Current Liabilities | 9.22 M |
| Non-Current Liabilities | 37.4 M |
| Long-Term Debt | 37.4 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Minerva Surgical, Inc.
| Revenue | 50.3 M |
| Cost Of Revenue | 23.1 M |
| Gross Profit | 27.2 M |
| Operating Expenses | 58.1 M |
| Operating Income | -30.9 M |
| Other Expenses | 3.21 M |
| Net Income | -34.1 M |
RATIOS
54.17%
GROSS MARGIN
-61.44%
OPERATING MARGIN
-67.83%
NET MARGIN
-198.54%
ROE
-49.51%
ROA
-54.69%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Minerva Surgical, Inc.
| Net Income | -34.1 M |
| Depreciation & Amortization | 10.8 M |
| Capital Expenditures | -73 K |
| Stock-Based Compensation | 6.98 M |
| Change in Working Capital | -11.1 M |
| Others | -14.3 M |
| Free Cash Flow | -35.6 M |
Wall Street Analysts Price Targets
Minerva Surgical, Inc.
UTRS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Minerva Surgical, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Feb 09, 2023
|
Bought 5 M USD
|
NEW ENTERPRISE ASSOCIATES 13 LP
10 percent owner |
+ 24437927
|
0.2046 USD |
|
2 years ago
Dec 13, 2021
|
Bought 123 K USD
|
Clapper David M
President and CEO |
+ 25000
|
4.9374 USD |
|
3 years ago
Oct 26, 2021
|
Bought 15.6 M USD
|
NEW ENTERPRISE ASSOCIATES 13 LP
10 percent owner |
+ 1300000
|
12 USD |
|
3 years ago
Oct 26, 2021
|
Bought 6.96 M USD
|
Novo Holdings A/S
10 percent owner |
+ 580000
|
12 USD |
7. News
Why Is Minerva Surgical (UTRS) Stock Down 50% Today?
Minerva Surgical (NASDAQ: UTRS ) stock is taking a beating on Monday after the women's healthcare company announced that its shares will be delisted later this month. According to a filing with the Securities and Exchange Commission (SEC), the company's shares will no longer trade on the Nasdaq Exchange starting on Dec. 29.
investorplace.com
- 11 months ago
Minerva Surgical Reports Third Quarter 2023 Financial Results
SANTA CLARA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported third quarter financial results for the period ended September 30, 2023.
globenewswire.com
- 1 year ago
Minerva Surgical, Inc. (UTRS) Q2 2023 Earnings Call Transcript
Minerva Surgical, Inc. (NASDAQ:UTRS ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Caroline Corner - IR Todd Usen - President & CEO Joel Jung - CFO Conference Call Participants Operator Greetings, and welcome to the Minerva Surgical Q2 2023 Earnings Call. At this time all participants are in listen-only mode.
seekingalpha.com
- 1 year ago
Minerva Surgical, Inc. (UTRS) Reports Q2 Loss, Misses Revenue Estimates
Minerva Surgical, Inc. (UTRS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.20 per share a year ago.
zacks.com
- 1 year ago
Minerva Surgical Reports Second Quarter 2023 Financial Results
SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023.
globenewswire.com
- 1 year ago
The Main Differences Between Penny Stocks and Blue Chips
Penny stocks and blue-chip stocks represent two distinct categories of equities that cater to different types of investors with varying risk appetites and investment goals. Understanding the fundamental differences between these two types of stocks is crucial for investors to make informed decisions and align their investment strategies with their financial objectives.
pennystocks.com
- 1 year ago
Best Penny Stocks Today? 3 Under $1 To Watch Now
If you're looking for the best penny stocks to buy today, you should be well-prepared to deal with high volatility. Whether it's the latest debt ceiling crisis, pandemic fear reemerging, today's Fed meeting minutes from May, or speeches by Janet Yellen and Federal Reserve members, there are plenty of headlines to contend with.
pennystocks.com
- 1 year ago
Why Is Minerva Surgical (UTRS) Stock Up 229% Today?
Minerva Surgical (NASDAQ: UTRS ) stock is rising higher on Wednesday despite a lack of news from the surgical and medical instrument manufacturing company. There have been no new press releases or filings with the Securities and Exchange Commission (SEC) that would explain why shares of UTRS stock are rising today.
investorplace.com
- 1 year ago
Minerva Surgical, Inc. (UTRS) Q1 2023 Earnings Call Transcript
Minerva Surgical, Inc. (NASDAQ:UTRS ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Caroline Corner - Investor Relations Todd Usen - President & CEO, Director Joel Jung - Chief Financial Officer Conference Call Participants Phillip Dantoin - Piper Sandler Operator Good day and thank you for standing by. Welcome to Minerva Surgical First Quarter 2023 Earnings Conference Call.
seekingalpha.com
- 1 year ago
Minerva Surgical to Announce First Quarter 2023 Financial Results
SANTA CLARA, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women, announced today that it will release its first quarter 2023 financial results on Tuesday, May 2, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
globenewswire.com
- 1 year ago
Minerva Surgical, Inc. (UTRS) Q4 2022 Earnings Call Transcript
Minerva Surgical, Inc. (NASDAQ:UTRS ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Caroline Corner - IR Todd Usen - President and CEO Joel Jung - CFO Conference Call Participants Operator Thank you for standing by, and welcome to Minerva's Fourth Quarter and Full Year 2022 Earnings Call. At this time, all participants are in a listen-only mode.
seekingalpha.com
- 1 year ago
Minerva Surgical to Announce Fourth Quarter and Full Year 2022 Financial Results
SANTA CLARA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
globenewswire.com
- 1 year ago
8. Profile Summary
Minerva Surgical, Inc. UTRS
COUNTRY
US
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 888
Dividend Yield
0.00%
Description
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Contact
4255 Burton Drive, Santa Clara, CA, 95054
https://minervasurgical.com
IPO Date
Oct. 22, 2021
Employees
174
Officers
Mr. Greg Simbro
Vice President of Finance
Mr. Erik Reese
Vice President of Sales
Ms. Wendy Bowman
Vice President of Human Resources
Ms. Joanne Long
Vice President of Corporate Controller
Mr. Darrin Hammers
Chief Executive Officer
Dr. Evgueni V. Skalnyi M.D.
Chief Medical Officer